Key terms
About CSTL
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CSTL news
Mar 27
5:23pm ET
Castle Biosciences Secures Loan and Reshuffles Board
Mar 20
4:55am ET
Castle Biosciences management to meet virtually with Stephens
Mar 15
3:32pm ET
Castle Biosciences management to meet virtually with Stephens
Mar 11
2:15am ET
Castle Biosciences: A Strong Buy on Genomic Diagnostic Leadership and Market Growth Potential
Mar 07
7:24am ET
Castle’s DecisionDx-SCC study shows predictive accurracy with patients
Mar 06
4:55am ET
Castle Biosciences management to meet with KeyBanc
Mar 05
8:01am ET
Castle Biosciences management to meet with KeyBanc
Mar 01
7:09am ET
Castle Biosciences price target raised to $37 from $33 at Scotiabank
Mar 01
6:33am ET
Castle Biosciences price target raised to $28 from $25 at KeyBanc
Mar 01
1:01am ET
Outperform Rating for Castle Biosciences Amid Strong Market Presence and Growth Prospects
Feb 29
9:00am ET
Analysts Conflicted on These Healthcare Names: Castle Biosciences (CSTL), DENTSPLY SIRONA (XRAY) and Silk Road Medical (SILK)
Feb 29
8:02am ET
Analysts Conflicted on These Healthcare Names: Immunocore Holdings (IMCR), Voyager Therapeutics (VYGR) and Castle Biosciences (CSTL)
Feb 29
6:49am ET
Castle Biosciences price target raised to $33 from $31 at Baird
Feb 28
5:27pm ET
Castle Biosciences files $300M mixed securities shelf
Feb 28
4:26pm ET
Castle Biosciences sees FY24 revenue $235M-$240M, consensus $214.7M
Feb 28
4:26pm ET
Castle Biosciences reports Q4 EPS (10c), consensus (54c)
Feb 28
4:23pm ET
Castle Biosciences Shapes Dialogue with Strategic Presentations
Jan 18
7:13am ET
Castle study shows DecisionDx -SCC test to guide radiation in cSCC reduces cost
Jan 15
8:18am ET
Castle presents data supporting utility of tests in care of skin cancer patients
Jan 09
12:57am ET
Buy Rating Affirmed for Castle Biosciences on Strong Performance and Positive Outlook
Jan 08
8:50am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jan 08
7:18am ET
Scotiabank Reaffirms Their Buy Rating on Castle Biosciences (CSTL)
Jan 07
8:05pm ET
Castle Biosciences reports preliminary FY23 revenue $210M, consensus $203.95M
Jan 07
5:26am ET
BTIG Reaffirms Their Buy Rating on Castle Biosciences (CSTL)
Jan 02
9:08am ET
BTIG Keeps Their Buy Rating on Castle Biosciences (CSTL)
Dec 31
5:11am ET
BTIG Sticks to Their Buy Rating for Castle Biosciences (CSTL)
No recent press releases are available for CSTL
CSTL Financials
Key terms
Ad Feedback
CSTL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CSTL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
